Discovering the Neural Basis of Human Social Anxiety: a Diagnostic and Therapeutic Imperative.

Back to table of contents Previous article Next article EditorialFull AccessDiscovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic ImperativeDennis S. Charney, M.D.Dennis S. Charney, M.D.Published Online:1 Jan 2004https://doi.org/10.1176/appi.ajp.161.1.1AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail Epidemiological studies indicate that generalized social anxiety disorder is among the most common of all psychiatric disorders, with lifetime prevalence estimates ranging from 7% to 12% (1). Social anxiety disorder is associated with considerable functional impairment and reduced quality of life (2, 3). Moreover, it has become increasingly apparent that disabling social anxiety accompanies other serious psychiatric disorders such as schizophrenia and depression, as highlighted in the papers by Pallanti et al. and Bruder et al. in this issue of the Journal. The report by Pallanti et al. is particularly instructive in this regard. They found that 36.3% of outpatients with schizophrenia met criteria for social anxiety disorder and that these patients had significantly higher lifetime rates of suicide attempts, greater lethality of attempts, more substance abuse, and lower overall quality of life. Social anxiety disorder is also frequently comorbid with major depression and atypical depression, which results in increased disability and reduced quality of life (3, 4). In fact, as emphasized by the findings of Kessler et al. (5), when the lifetime prevalence of major depression is considered, depression is frequently comorbid with anxiety disorders and is only rarely primary. These data emphasize the importance of understanding the etiology and pathogenesis of social anxiety, not only in the context of social anxiety disorder as a discrete entity as defined by DSM-IV but also when comorbid with other neuropsychiatric disorders. The phenotypic expression of social anxiety depends on both genetic and environmental factors. Investigations by Schwartz et al. (6) have shown that behavioral inhibition to novelty very early in life increases the risk for the development of social anxiety disorder later in life, suggesting the importance of genetic factors. Stein and associates (7) have found that a cognitive dimension (as measured by the Fear of Negative Evaluation Scale) related to the experience of social anxiety was moderately heritable. Preclinical studies have also suggested that specific genes may contribute to social behaviors (8). Twin and family studies have suggested that both genetic and environmental factors contribute to social anxiety (9). For example, parental psychopathology (particularly social anxiety and depression) and parental style (overprotection and rejection) may interact with a genetic predisposition to increase the risk of social anxiety disorder (10). Insufficient attention has been paid toward elucidating the neurobiological basis of social anxiety. Few neuroimaging studies of social anxiety disorder patients have been conducted. One noteworthy investigation reported preliminary evidence of amygdala hyperactivity in response to angry and contemptuous faces (11). The neurochemical modulation of social anxiety has also scarcely been studied; a role for dopamine and serotonin neural systems has been suggested (12). In this context, the paper by Bruder and colleagues in this issue of the Journal is welcome. The primary finding of their study was that patients with social anxiety disorder with or without comorbid depression had a decreased left hemispheric advantage for processing words or syllables. As noted by the authors, the reduced left hemisphere processing is not specific to patients with social anxiety in that it is also observed in patients with obsessive-compulsive disorder (13) and schizophrenia (14, 15). Their speculation that the deficit in the left hemisphere processing of verbal stimuli may have clinical relevance to the anxiety experienced in social situations and may be related to the mechanisms of action of cognitive behavior therapy deserves further study. Disabling social anxiety is a major public health problem (16). It is not restricted to social anxiety disorder but is an important symptomatic feature of numerous psychiatric disorders. The observations that the experience of social anxiety span DSM-IV-based conditions provide another example of the limitations of a diagnostic system not based upon etiology (17). Spectacular advances in the cognitive neuroscience of social behavior (18) provide a framework from which to investigate the neural basis of social anxiety (19). In the near future, it will be important to determine if the etiology of social anxiety varies depending upon the co-occurring psychiatric disorders. These investigations promise to contribute to identification of new molecular targets relevant to drug treatment discovery and novel psychotherapeutic approaches for social anxiety. Address reprint requests to Dr. Charney, Mood and Anxiety Disorders Research Program, National Institute of Mental Health, 9000 Rockville Pike, Bethesda, MD 20892.References1. Wittchen HU, Fehm L: Epidemiology, patterns of comorbidity, and associated disabilities of social phobia. Psychiatric Clin North Am 2001; 24:617–664 Crossref, Medline, Google Scholar2. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, Street L, Del Bene D, Liebowitz MR: Functional impairment in social phobia. J Clin Psychiatry 1994; 55:322–331 Medline, Google Scholar3. Lochner C, Mogotsi M, du Toit PL, Kaminer D, Niehaus DJ, Stein DJ: Quality of life in anxiety disorders: a comparison of obsessive-compulsive disorder, social anxiety disorder, and panic disorder. Psychopathology 2003; 36:255–262 Crossref, Medline, Google Scholar4. Matza LS, Revicki DA, Davidson JR, Stewart JW: Depression with atypical features in the national comorbidity survey. Arch Gen Psychiatry 2003; 60:817–826 Crossref, Medline, Google Scholar5. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095–3105 Crossref, Medline, Google Scholar6. Schwartz CE, Snidman N, Kagan J: Adolescent social anxiety as an outcome of inhibited temperament in childhood. J Am Acad Child Adolesc Psychiatry 1999; 38:1008–1015 Crossref, Medline, Google Scholar7. Stein MB, Lang KL, Livesley WJ: Heritability of social anxiety-related concerns and personality characteristics: a twin study. J Nerv Ment Dis 2002; 190:219–224 Crossref, Medline, Google Scholar8. Insel TR, Young LJ: The neurobiology of attachment. Nature Reviews Neuroscience 2001; 129–136Google Scholar9. Kendler KS, Karkowski LM, Prescott CA: Fears and phobias: reliability and heritability. Psychol Med 1999; 29:539–553 Crossref, Medline, Google Scholar10. Lieb R, Wittchen HU, Hofler M, Fuetsch M, Stein MB, Merikangas KR: Parental psychopathology, parenting styles, and the risk of social phobia in offspring: a prospective-longitudinal community study. Arch Gen Psychiatry 2000; 57:859–866 Crossref, Medline, Google Scholar11. Stein MB, Goldin PR, Sareen J, Zorrilla LTE, Brown GG: Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch Gen Psychiatry 2002; 59:1027–1034 Crossref, Medline, Google Scholar12. Mathew SJ, Coplan JD, Gorman JM: Neurobiological mechanisms of social anxiety disorder. Am J Psychiatry 2001; 158:1558–1567 Link, Google Scholar13. Wexler BE, Goodman WK; Cerebral laterality, perception of emotion, and treatment response in obsessive-compulsive disorder. Biol Psychiatry 1991; 29:900–908 Crossref, Medline, Google Scholar14. Wexler BE, Giller EL Jr, Southwick S: Cerebral laterality, symptoms, and diagnosis in psychotic patients. Biol Psychiatry 1991; 29:103–116 Crossref, Medline, Google Scholar15. Asbjörnsen A, Hugdahl K, Bryden MP: Manipulations of subjects' level of arousal in dichotic listening. Brain Cogn 1992; 19:183–194 Crossref, Medline, Google Scholar16. Kessler RC: The impairments caused by social phobia in the general population: implications for intervention. Acta Psychiatr Scand Suppl 2003; 417:19–27 Crossref, Medline, Google Scholar17. Charney DS, Barlow DH, Botteron K, Cohen JD, Goldman D, Gur RE, Lin KM, Lopez JF, Meador-Woodruff JH, Moldin SO, Nestler EJ, Watson SJ, Zalcman SJ: Neuroscience research agenda to guide development of a pathophysiologically based classification system, in A Research Agenda for DSM-V. Edited by Kupfer DJ, First MB, Regier DA. Washington, DC, American Psychiatric Association, 2002, pp 31–83Google Scholar18. Adolphs R: Cognitive neuroscience of human social behavior. Nature Reviews 2003; 4:165–178 Crossref, Medline, Google Scholar19. Eisenberger NI, Lieberman MD, Williams KP: Does rejection hurt? An fMRI study of social exclusion. Science 2003; 302:290–292 Crossref, Medline, Google Scholar FiguresReferencesCited byDetailsCited byA study on the changing trend and influencing factors of hospitalization costs of schizophrenia in economically underdeveloped areas of China19 January 2023 | Schizophrenia, Vol. 9, No. 1Efficacy of low-dose risperidone in combination with sertraline in first-episode drug-naïve patients with schizophrenia: a randomized controlled open-label study4 July 2023 | Journal of Translational Medicine, Vol. 21, No. 1Association between enhanced carbonyl stress and decreased apparent axonal density in schizophrenia by multimodal white matter imaging27 July 2023 | Scientific Reports, Vol. 13, No. 1A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia1 August 2023 | European Archives of Psychiatry and Clinical Neuroscience, Vol. 45Disrupted subcortical functional connectome gradient in drug-naïve first-episode schizophrenia and the normalization effects after antipsychotic treatment10 December 2022 | Neuropsychopharmacology, Vol. 48, No. 5Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia7 February 2023 | BMJ Mental Health, Vol. 26, No. 1Unemployment, homelessness, and other societal outcomes in patients with schizophrenia: a real-world retrospective cohort study of the United States Veterans Health Administration database8 July 2022 | BMC Psychiatry, Vol. 22, No. 1Tracking Positive and Negative Symptom Improvement in First-Episode Schizophrenia Treated with Risperidone Using Individual-Level Functional ConnectivityBrain Connectivity, Vol. 12, No. 5Antipsychotic drug dose in real-life settings results from a Nationwide Cohort Study22 August 2021 | European Archives of Psychiatry and Clinical Neuroscience, Vol. 272, No. 4Variation in Psychotropic Medication Prescription for Adults With Schizophrenia in the United StatesNatalie Bareis, L.M.S.W., Ph.D., Mark Olfson, M.D., M.P.H., Melanie Wall, Ph.D., T. Scott Stroup, M.D., M.P.H.30 September 2021 | Psychiatric Services, Vol. 73, No. 5Cognitive Behavioral Therapy for PsychosisKorean Journal of Schizophrenia Research, Vol. 25, No. 1Correlates of high-dose antipsychotic prescription amongst outpatients with Schizophrenia in a Nigerian Hospital29 April 2022 | South African Journal of Psychiatry, Vol. 28Rare coding variants in ten genes confer substantial risk for schizophrenia8 April 2022 | Nature, Vol. 604, No. 7906Association between depression in chronic phase and future clinical outcome of patients with schizophrenia21 February 2022 | Psychopharmacology, Vol. 239, No. 3Impact of drug-induced Parkinsonism and tardive dyskinesia on health-related quality of life in schizophrenia3 January 2022 | Journal of Psychopharmacology, Vol. 36, No. 2A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance12 October 2021 | Molecular Psychiatry, Vol. 27, No. 2Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs1 April 2022 | Neuropsychiatric Disease and Treatment, Vol. Volume 18Atypical Treatment Switches in Schizophrenia Patients: Drivers and Associated Outcomes1 May 2022 | Neuropsychiatric Disease and Treatment, Vol. Volume 18Preferences for WeChat-Based and Hospital-Based Family Intervention Among Caregivers of People Living with Schizophrenia1 March 2022 | Patient Preference and Adherence, Vol. Volume 16Treatment resistance in psychiatry: state of the art and new directions13 July 2021 | Molecular Psychiatry, Vol. 27, No. 1Effect of Delayed Clozapine Initiation on Acute Treatment Response in Treatment-Resistant SchizophreniaKorean Journal of Schizophrenia Research, Vol. 24, No. 2Differences in Antipsychotic Treatment Discontinuation Among Veterans With Schizophrenia in the U.S. Department of Veterans AffairsMark Weiser, M.D., John M. Davis, M.D., Clayton H. Brown, Ph.D., Eric P. Slade, Ph.D., Li Juan Fang, M.S., Deborah R. Medoff, Ph.D., Robert W. Buchanan, M.D., Linda Levi, B.Sc., Michael Davidson, M.D., Julie Kreyenbuhl, Pharm.D., Ph.D.14 July 2021 | American Journal of Psychiatry, Vol. 178, No. 10Convolutional neural network in proteomics and metabolomics for determination of comorbidity between cancer and schizophreniaJournal of Biomedical Informatics, Vol. 122A Program to Increase the Appropriate Use of Long-Acting Injectable Antipsychotic Medications in Community SettingsDawn I. Velligan, Ph.D., Martha Sajatovic, M.D., Cynthia Sierra, M.A., Jim Mintz, Ph.D., Julie M. Merker, M.S.U.S., Kristin A. Cassidy, M.A., Patrick Runnels, M.D.21 May 2021 | Psychiatric Services, Vol. 72, No. 9A unique missense variant in the E1A-binding protein P400 gene is implicated in schizophrenia by whole-exome sequencing and mutant mouse models18 February 2021 | Translational Psychiatry, Vol. 11, No. 1Clinical use of neuro-imaging in psychiatric patients at the Charlotte Maxeke Johannesburg Academic Hospital28 May 2021 | South African Journal of Psychiatry, Vol. 27Identification of clinical phenotypes in schizophrenia: the role of lurasidone10 May 2021 | Therapeutic Advances in Psychopharmacology, Vol. 11Prescription attitudes and practices regarding clozapine among Serbian psychiatrists: results of a nationwide survey29 May 2021 | Therapeutic Advances in Psychopharmacology, Vol. 11The effect of non-adherence to antipsychotic treatment on rehospitalization in patients with psychotic disorders25 June 2021 | Therapeutic Advances in Psychopharmacology, Vol. 11Cariprazine in Three Special Different Areas: A Real-World Experience1 December 2021 | Neuropsychiatric Disease and Treatment, Vol. Volume 17Dopamine and Response to Antipsychotic Medication15 December 2020The use of clozapine is protective for low bone mineral density induced by prolactin-raising antipsychotics in inpatients with schizophrenia29 June 2020 | Archives of Osteoporosis, Vol. 15, No. 1Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine17 July 2020 | npj Schizophrenia, Vol. 6, No. 1Functional MRI in the effect of transcranial magnetic stimulation therapy for patients with schizophrenia: a meta-analysis protocol2 December 2020 | BMJ Open, Vol. 10, No. 12The use of olanzapine as an antiemetic in palliative medicine: a systematic review of the literature22 April 2020 | BMC Palliative Care, Vol. 19, No. 1Treatment-Resistant Schizophrenia: Terminology and Clinical FeaturesKorean Journal of Schizophrenia Research, Vol. 23, No. 2Variability in Price of Generic Antipsychotic Medications at Community PharmaciesCarrie R. Kriz, M.S., Leigh Anne Nelson, Pharm.D., B.C.P.P., Lakshmi Venkitachalam, Ph.D., Jenifer E. Allsworth, Ph.D., An-Lin Cheng, Ph.D., Roger W. Sommi, Pharm.D., B.C.P.P.24 June 2020 | Psychiatric Services, Vol. 71, No. 10Social support and Posttraumatic Stress Disorder (PTSD) in earthquake survivors: a systematic review31 July 2020 | Social Work in Mental Health, Vol. 18, No. 5Wnt receptor gene FZD1 was associated with schizophrenia in genome-wide SNP analysis of the Australian Schizophrenia Research Bank cohort16 November 2019 | Australian & New Zealand Journal of Psychiatry, Vol. 54, No. 9Assessment of Real-Life Outcomes in Schizophrenia Patients according to CompliancePsychiatry Journal, Vol. 2020Replacing Unhealthy EE with Healthy EE in Schizophrenia: Towards a Public Health Model of Cognitive Rehabilitation for Low-Resource Settings21 July 2020 | Journal of Psychosocial Rehabilitation and Mental Health, Vol. 7, No. 2Treating schizophrenia: the quality of evidence behind treatment recommendations and how it can improve31 October 2019 | BMJ Evidence-Based Medicine, Vol. 25, No. 4Treatment Persistence Between Long-Acting Injectable Versus Orally Administered Aripiprazole Among Patients with Schizophrenia in a Real-World Clinical Setting in Japan4 June 2020 | Advances in Therapy, Vol. 37, No. 7RE-KINECT19 April 2020 | Journal of Clinical Psychopharmacology, Vol. 40, No. 3Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology12 December 2019 | Journal of Psychopharmacology, Vol. 34, No. 1Check the effects: systematic assessment of antipsychotic side-effects in an inpatient cohort25 September 2020 | Therapeutic Advances in Psychopharmacology, Vol. 10 Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies 1 June 2020 | Neuropsychiatric Disease and Treatment, Vol. Volume 16 Attitude Towards Drug Therapy in a Community Mental Health Center Evaluated by the Drug Attitude Inventory 1 June 2020 | Patient Preference and Adherence, Vol. Volume 14 Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey 1 October 2020 | Patient Preference and Adherence, Vol. Volume 14Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate1 August 2019 | npj Schizophrenia, Vol. 5, No. 1Onset of schizophrenia diagnoses in a large clinical cohort8 July 2019 | Scientific Reports, Vol. 9, No. 1Prescription practices in the treatment of agitation in newly hospitalized Chinese schizophrenia patients: data from a non-interventional naturalistic study10 July 2019 | BMC Psychiatry, Vol. 19, No. 1Long-Term Response to Clozapine and Its Clinical Correlates in the Treatment of Tardive Movement Syndromes30 October 2019 | Journal of Clinical Psychopharmacology, Vol. 39, No. 6Monthly Extended-Release Risperidone (RBP-7000) in the Treatment of Schizophrenia24 July 2019 | Journal of Clinical Psychopharmacology, Vol. 39, No. 5Clozapine-induced stercoral colitis: a surgical perspective30 August 2019 | BMJ Case Reports, Vol. 12, No. 8CDI cross-linked β-cyclodextrin nanosponges of paliperidone: synthesis and physicochemical characterization13 June 2019 | Journal of Materials Science: Materials in Medicine, Vol. 30, No. 6Long-acting atypical antipsychotics in schizophrenia: A systematic review and meta-analyses of effects on functional outcome8 April 2019 | Australian & New Zealand Journal of Psychiatry, Vol. 53, No. 6Antipsychotic-induced tardive dyskinesiaCurrent Opinion in Psychiatry, Vol. 32, No. 3Effects of Neonatal Administration of Memantine on Hippocampal Asymmetry and Working Memory Impairment Induced by Early Maternal Deprivation in Rats31 July 2019 | Neurophysiology, Vol. 51, No. 2Acta Neuropsychiatrica, Vol. 31, No. 03The Journal of Nervous and Mental Disease, Vol. 207, No. 2The Association of Lifetime Suicide Attempts With Anxiety Disorders in Patients With Bipolar DisorderJournal of Psychiatric Practice, Vol. 25, No. 1International Clinical Psychopharmacology, Vol. 34, No. 5Journal of Psychopharmacology, Vol. 33, No. 10BJPsych Advances, Vol. 25, No. 05Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan12 October 2018 | Australian & New Zealand Journal of Psychiatry, Vol. 52, No. 12The Lara case: A group analysis of initial psychoanalytic interviews using systematic clinical observation and empirical tools15 January 2019 | The International Journal of Psychoanalysis, Vol. 99, No. 6Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil27 July 2018 | Applied Health Economics and Health Policy, Vol. 16, No. 5TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel4 May 2018 | Therapeutic Advances in Psychopharmacology, Vol. 8, No. 10Use of Academic Detailing With Audit and Feedback to Improve Antipsychotic PharmacotherapyMary F. Brunette, M.D., Robert O. Cotes, M.D., Alexander de Nesnera, M.D., Gregory McHugo, Ph.D., Nino Dzebisashvili, Ph.D., Haiyi Xie, Ph.D., Stephen J. Bartels, M.D., M.S.8 June 2018 | Psychiatric Services, Vol. 69, No. 9Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008–2014Cynthia A. Fontanella, Ph.D., Danielle L. Hiance-Steelesmith, Ph.D., Hossam Guirgis, M.D., John V. Campo, M.D.2 July 2018 | Psychiatric Services, Vol. 69, No. 9Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics28 February 2018 | Current Medical Research and Opinion, Vol. 34, No. 8PsychosisCONTINUUM: Lifelong Learning in Neurology, Vol. 24, No. 3New findings in pharmacogenetics of schizophreniaCurrent Opinion in Psychiatry, Vol. 31, No. 3Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study1 March 2018 | Journal of Psychopharmacology, Vol. 32, No. 5Journal of Mental Health, Vol. 27, No. 4Journal of Clinical Psychopharmacology, Vol. 38, No. 5International Clinical Psychopharmacology, Vol. 33, No. 3International Clinical Psychopharmacology, Vol. 33, No. 4BMC Psychiatry, Vol. 18, No. 1BMC Psychiatry, Vol. 18, No. 1BMC Health Services Research, Vol. 18, No. 1Journal of Doctoral Nursing Practice, Vol. 11, No. 1Clinical Schizophrenia & Related Psychoses, Vol. 12, No. 2Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic DisordersJournal of Clinical Psychopharmacology, Vol. 37, No. 3GWAS analysis of treatment resistant schizophrenia: interaction effect of childhood traumaPharmacogenomics, Vol. 18, No. 7Treatment Duration With Long-Acting Injectable Antipsychotics After In-hospital InitiationJournal of Clinical Psychopharmacology, Vol. 37, No. 2The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis9 February 2016 | The Pharmacogenomics Journal, Vol. 17, No. 2Personal Accounts of Discontinuing Neuroleptic Medication for Psychosis9 July 2016 | Qualitative Health Research, Vol. 27, No. 4Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams15 December 2016 | Therapeutic Advances in Psychopharmacology, Vol. 7, No. 3, Vol. 10191Journal of Neural Transmission, Vol. 124, No. 7Advances in Therapy, Vol. 34, No. 11Journal of Clinical Psychopharmacology, Vol. 37, No. 3International Clinical Psychopharmacology, Vol. 32, No. 3International Clinical Psychopharmacology, Vol. 32, No. 5International Clinical Psychopharmacology, Vol. 32, No. 6The Nursing Assessment of Medication Acceptance: the reliability and validity of a schizophrenia medication adherence scale7 October 2016 | Therapeutic Advances in Psychopharmacology, Vol. 7, No. 1BMC Psychiatry, Vol. 17, No. 1BMC Psychiatry, Vol. 17, No. 1International Journal of Mental Health Systems, Vol. 11, No. 1Trials, Vol. 18, No. 1Comparison of Hematologic Variability between Clozapine Monotherapy and Augmentation Therapy with Atypical Antipsychotics for Schizophrenia: Results from a 6-Month Retrospective Follow-Up StudyKorean Journal of Schizophrenia Research, Vol. 20, No. 2Korean Journal of Schizophrenia Research, Vol. 20, No. 2Clinical Schizophrenia & Related Psychoses, No. aopThe Business Case for Expanded Clozapine UtilizationJessica L. Gören, Pharm.D., Adam J. Rose, M.D., M.Sc., Eric G. Smith, M.D., Ph.D., John P. Ney, M.D., M.P.H.15 June 2016 | Psychiatric Services, Vol. 67, No. 11Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-AnalysisBartosz Helfer, M.Sc., Myrto T. Samara, M.D., Maximilian Huhn, M.D., Elisabeth Klupp, M.D., Claudia Leucht, M.D., Yikang Zhu, M.Med., Rolf R. Engel, Ph.D., Stefan Leucht, M.D.10 June 2016 | American Journal of Psychiatry, Vol. 173, No. 9The SWITCH study: rationale and design of the trial31 July 2015 | European Archives of Psychiatry and Clinical Neuroscience, Vol. 266, No. 6Antipsychotics decrease response confidence24 May 2016 | Journal of Psychopharmacology, Vol. 30, No. 8Psychosis, antipsychotics and premature mortality: The elephant in the room1 August 2016 | Clinical Psychology Forum, Vol. 1, No. 284Is the Evidence Strong Enough to Warrant Long-Term Antipsychotic Use in Compulsory Outpatient Treatment?Shawn S. Barnes, M.D., and Nicolas Badre, M.D.15 March 2016 | Psychiatric Services, Vol. 67, No. 7Antipsychotic Medication Prescribing Practices Among Adult Patients Discharged From State Psychiatric Inpatient HospitalsJournal of Psychiatric Practice, Vol. 22, No. 4Short term effectiveness of haloperidol versus risperidone in first-episode schizophrenia3 December 2015 | Proceedings of Singapore Healthcare, Vol. 25, No. 2Cross-sectional comparison of first-generation antipsychotic long-acting injections vs risperidone long-acting injection: patient-rated attitudes, satisfaction and tolerability10 March 2016 | Therapeutic Advances in Psychopharmacology, Vol. 6, No. 3Neurology and Therapy, Vol. 5, No. 2Schizophrenia Research, Vol. 176, No. 2-3International Journal of NeuropsychopharmacologySchizophrenia Bulletin, Vol. 42, No. suppl 1Schizophrenia BulletinThe Role of Protein Kinase A in Anxiety Behaviors4 March 2016 | Neuroendocrinology, Vol. 103, No. 6Expert Opinion on Pharmacotherapy, Vol. 17, No. 7Clinical Practice & Epidemiology in Mental Health, Vol. 12, No. 1Experimental Neurobiology, Vol. 25, No. 6Schizophrene Psychosen2 November 2016Are Second-Generation Antipsychotics Useful in Tardive Dystonia?Clinical Neuropharmacology, Vol. 38, No. 5Transatlantic variation in the attributed etiology of psychosis30 December 2014 | International Journal of Social Psychiatry, Vol. 61, No. 6Health Care Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia TreatmentJournal of Managed Care & Specialty Pharmacy, Vol. 21, No. 9The Swiss Cohort Study on Substance Use Risk Factors – Findings of two WavesSUCHT, Vol. 61, No. 4Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital DischargeJournal of Clinical Psychopharmacology, Vol. 35, No. 4Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test ReviewMyrto T. Samara, M.D., Claudia Leucht, M.D., Mariska M. Leeflang, Ph.D., Ion-George Anghelescu, M.D., Young-Chul Chung, Ph.D., M.D., Benedicto Crespo-Facorro, Ph.D., M.D., Helio Elkis, Ph.D., M.D., Kotaro Hatta, Ph.D., M.D., Ina Giegling, Ph.D., John M. Kane, M.D., Monica Kayo, M.D., Martin Lambert, M.D., Ching-Hua Lin, Ph.D., M.D., Hans-Jürgen Möller, Ph.D., M.D., José María Pelayo-Terán, Ph.D., M.D., Michael Riedel, M.D., Dan Rujescu, Ph.D., M.D., Benno G. Schimmelmann, M.D., Alessandro Serretti, Ph.D., M.D., Christoph U. Correll, M.D., Stefan Leucht, M.D.5 June 2015 | American Journal of Psychiatry, Vol. 172, No. 7Patients' Preferences Related to Benefits, Risks, and Formulations of Schizophrenia TreatmentBennett Levitan, M.D., Ph.D., Michael Markowitz, M.D., M.S.P.H., Ateesha F. Mohamed, M.A., F. Reed Johnson, Ph.D., Larry Alphs, M.D., Ph.D., Leslie Citrome, M.D., M.P.H., John F. P. Bridges, Ph.D.16 March 2015 | Psychiatric Services, Vol. 66, No. 7Vintage treatments for PTSD: A reconsideration of tricyclic drugs13 January 2015 | Journal of Psychopharmacology, Vol. 29, No. 3Der Nervenarzt, Vol. 86, No. 12Psychopharmacology, Vol. 232, No. 1The impact of psychological traumaAnxiety, Stress, & Coping, Vol. 28, No. 2International Journal for Quality in Health Care, Vol. 27, No. 4Schizophrenia Bulletin, Vol. 41, No. 6Korean Journal of Schizophrenia Research, Vol. 18, No. 1Journal of Managed Care & Specialty Pharmacy, Vol. 21, No. 9International Journal of Psychiatry in Clinical Practice, Vol. 19, No. 2Cognitive Behavioural Therapy for Co-occurring Obsessive-Compulsive Symptoms7 February 2015Clinical predictors of therapeutic response to antipsychotics in schizophrenia1 April 2022 | Dialogues in Clinical Neuroscience, Vol. 16, No. 4Differences Between Patients With Schizophrenia With and Without Co-Occurring Methamphetamine Use Disorders in a Taiwanese Public Psychiatric HospitalJournal of Nervous & Mental Disease, Vol. 202, No. 11The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal2 July 2014 | Therapeutic Advances in Psychopharmacology, Vol. 4, No. 5A qualitative study of the